Inhibidores de la proteína transferidora de ésteres de colesterol. ¿Cuál es su futuro?

2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet, 366, 1267, 10.1016/S0140-6736(05)67394-1 Barter, 2007, HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events, N Engl J Med, 357, 1301, 10.1056/NEJMoa064278 Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL: a complex process unrelated to changes in LDL: analysis of the VOYAGER database. J Lipid Res. 2009. Epub ahead of print. Birjmohun, 2005, Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials, J Am Coll Cardiol, 45, 185, 10.1016/j.jacc.2004.10.031 Brown, 2006, Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials, Curr Opin Lipidol, 17, 631, 10.1097/MOL.0b013e32800ff750 Chapman, 2010, Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors, Eur Heart J, 31, 149, 10.1093/eurheartj/ehp399 Niesor, 2008, Inhibition of cholesteryl ester transfer protein (CETP): different in vitro characteristics of RO4607381/JTT-705 and torcetrapib (TOR), Atherosclerosis, 199, 231, 10.1016/j.atherosclerosis.2008.04.024 Okamoto, 2000, A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits, Nature, 406, 203, 10.1038/35018119 De Grooth, 2002, Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose response study, Circulation, 105, 2159, 10.1161/01.CIR.0000015857.31889.7B Kuivenhoven, 2005, Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia, Am J Cardiol, 95, 1085, 10.1016/j.amjcard.2004.12.064 Stein, 2009, Safety and tolerability of dalcetrapib, Am J Cardiol, 104, 82, 10.1016/j.amjcard.2009.02.061 Stroes, 2009, Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats, Br J Pharmacol, 158, 1763, 10.1111/j.1476-5381.2009.00460.x Niesor, 2009, The effects of dalcetrapib on macrophage reverse cholesterol transport in a rodent model, Circulation, 120, S468 Schwartz, 2009, Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome, Am Heart J, 158, 896, 10.1016/j.ahj.2009.09.017 Hermann, 2009, Cholesteryl ester transfer protein inhibition and endothelial function in type II hyperlipidemia, Thromb Res, 123, 460, 10.1016/j.thromres.2008.06.022 National Institutes of Health. A study of the effect of RO4607381 on atherosclerotic plaque in patients with coronary heart disease. Disponible en: http://clinicaltrials.gov/ct2/show?term=RO4607381&rank=4 Krishna, 2007, Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies, Lancet, 370, 1907, 10.1016/S0140-6736(07)61813-3 Bloomfield, 2009, Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients, Am Heart J, 157, 352, 10.1016/j.ahj.2008.09.022 Cannon, 2009, Design of the DEFINE trial: Determining the EFficacy and tolerability of CETP INhibition with anacEtrapib, Am Heart J, 158, 513, 10.1016/j.ahj.2009.07.028 Tall, 2009, The effects of cholesterol ester transfer protein inhibition on cholesterol efflux, Am J Cardiol, 104, 39E, 10.1016/j.amjcard.2009.09.018